269 related articles for article (PubMed ID: 22041253)
1. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.
Hexsel D; Brum C; do Prado DZ; Soirefmann M; Rotta FT; Dal'Forno T; Rodrigues TC
J Am Acad Dermatol; 2012 Aug; 67(2):226-32. PubMed ID: 22041253
[TBL] [Abstract][Full Text] [Related]
2. Comparing the clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA utilizing a novel contralateral Frontalis model and the Frontalis Activity Measurement Standard.
Nestor MS; Ablon GR
J Drugs Dermatol; 2011 Oct; 10(10):1148-57. PubMed ID: 21968665
[TBL] [Abstract][Full Text] [Related]
3. Fields of effects of 2 commercial preparations of botulinum toxin type A at equal labeled unit doses: a double-blind randomized trial.
Hexsel D; Hexsel C; Siega C; Schilling-Souza J; Rotta FT; Rodrigues TC
JAMA Dermatol; 2013 Dec; 149(12):1386-91. PubMed ID: 24108521
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles.
Michaels BM; Csank GA; Ryb GE; Eko FN; Rubin A
Aesthet Surg J; 2012 Jan; 32(1):96-102. PubMed ID: 22231417
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin: examining duration of effect in facial aesthetic applications.
Flynn TC
Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
[TBL] [Abstract][Full Text] [Related]
6. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A.
Hexsel D; Dal'Forno T; Hexsel C; Do Prado DZ; Lima MM
Dermatol Surg; 2008 Jan; 34(1):52-9. PubMed ID: 18053050
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
[TBL] [Abstract][Full Text] [Related]
8. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
Matarasso A; Shafer D
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S72-9. PubMed ID: 19945008
[TBL] [Abstract][Full Text] [Related]
9. A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides.
Carruthers A; Carruthers J; Cohen J
Dermatol Surg; 2003 May; 29(5):461-7. PubMed ID: 12752512
[TBL] [Abstract][Full Text] [Related]
10. Comparison of four botulinum neurotoxin type A preparations in the treatment of hyperdynamic forehead lines in men: a pilot study.
Oliveira de Morais O; Matos Reis-Filho E; Vilela Pereira L; Martins Gomes C; Alves G
J Drugs Dermatol; 2012 Feb; 11(2):216-9. PubMed ID: 22270205
[TBL] [Abstract][Full Text] [Related]
11. Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox.
Yang GC; Chiu RJ; Gillman GS
Arch Facial Plast Surg; 2008; 10(4):273-9. PubMed ID: 18645097
[TBL] [Abstract][Full Text] [Related]
12. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
Kim SB; Ban B; Jung KS; Yang GH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
[TBL] [Abstract][Full Text] [Related]
13. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Baumann L; Brandt FS; Kane MA; Donofrio LM
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
[TBL] [Abstract][Full Text] [Related]
14. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience.
Farahvash MR; Arad S
J Cosmet Dermatol; 2007 Sep; 6(3):152-8. PubMed ID: 17760691
[TBL] [Abstract][Full Text] [Related]
15. Treatment of forehead/glabellar rhytide complex with combination botulinum toxin a and hyaluronic acid versus botulinum toxin A injection alone: a split-face, rater-blinded, randomized control trial.
Dubina M; Tung R; Bolotin D; Mahoney AM; Tayebi B; Sato M; Mulinari-Brenner F; Jones T; West DP; Poon E; Nodzenski M; Alam M
J Cosmet Dermatol; 2013 Dec; 12(4):261-6. PubMed ID: 24305424
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Clinical Efficacy of Abobotulinumtoxin A (ABO) and Onabotulinumtoxin A (ONA) in the Treatment of Crow's Feet Wrinkles: A Split-Face Study.
Elridy AS; Zaki RGE; Elshinawy RF
Semin Ophthalmol; 2018; 33(6):739-747. PubMed ID: 29278961
[TBL] [Abstract][Full Text] [Related]
17. RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: an evaluator-blind, randomized, pilot study.
Lee DH; Kang SM; Feneran A; Youn CS; Kim JK; Cho S; Won CH; Chang SE; Lee MW; Choi JH; Moon KC
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e1-7. PubMed ID: 23030660
[TBL] [Abstract][Full Text] [Related]
18. Dosing, efficacy and safety plus the use of computerized photography for botulinum toxins type A for upper facial lines.
Lowe NJ; Shah A; Lowe PL; Patnaik R
J Cosmet Laser Ther; 2010 Apr; 12(2):106-11. PubMed ID: 20151785
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.
Kane MA; Gold MH; Coleman WP; Jones DH; Tanghetti EA; Alster TS; Rohrer TE; Burgess CM; Shamban AT; Finn E
Dermatol Surg; 2015 Nov; 41(11):1310-9. PubMed ID: 26509943
[TBL] [Abstract][Full Text] [Related]
20. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines.
Glogau R; Blitzer A; Brandt F; Kane M; Monheit GD; Waugh JM
J Drugs Dermatol; 2012 Jan; 11(1):38-45. PubMed ID: 22206075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
